Regeneron Collaborates with BioNTech to Advance the Combination of FixVac and Libtayo (cemiplimab) in Melanoma

 Regeneron Collaborates with BioNTech to Advance the Combination of FixVac and Libtayo (cemiplimab) in Melanoma

Regeneron Collaborates with BioNTech to Advance the Combination of FixVac and Libtayo (cemiplimab) in Melanoma

Shots:

  • The two companies collaborated to jointly conduct P-II study combining BNT111 FixVac and Libtayo in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV cutaneous melanoma with the expected initiation of the study in Q4’20
  • The companies will equally share the development costs for the clinical trial and will contribute their products for the trial. Each party will retain full commercial rights for its respective product and record revenues related to its own product
  • Additionally, the companies plan to pursue a clinical trial for the combination in a 2L setting for advanced melanoma. The combination therapy has the potential to augment the immune system’s ability to effectively recognize melanoma in multiple ways and to improve immune to control the cancer

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: OrthoSpine News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post